Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
'Under construction' by Lara Crow, inspired by the Reviews on p321 and p361, which discuss microRNA biogenesis and building better therapeutic monoclonal antibodies, respectively.
Two different devices have been developed to deliver cancer drugs directly into tumoursin vivoto evaluate cell penetration, drug stability and effectiveness.
Liuet al. show that the mushroom-derived toxin α-amanitin, conjugated to antibodies against a tumour-specific biomarker, might be effective therapeutically (with minimal toxicity) for tumours that have hemizygous deletions of TP53 that also encompass POLR2A.
The microRNA (miRNA) biogenesis pathway is frequently altered in cancer, leading to global downregulation of miRNA levels in some cancer types. This Review discusses the alterations that affect miRNA biogenesis in cancer.
Histone–lysineN-methyltransferase 2 (KMT2) family proteins, initially named the mixed lineage leukaemia (MLL) family, are altered in many types of cancers beyond MLL. Inhibitors of KMT2 function are being developed and could work as therapeutics in a variety of cancer types.
The modern manufacture of tumour-selective antibodies bearing tumour-killing radioactive cargo has effectively harnessed the power of the atom to safely destroy cancer cells. This Review presents fundamental concepts of chemistry, physics and biology that are essential for the effective radioimmunotherapy of human cancer.
How can we improve the design of monoclonal antibodies (mAbs) to treat cancer? In this Review, George J. Weiner discusses the characteristics of mAbs that can affect their efficacy, the current approaches that use mAbs in cancer treatment and the numerous ways to enhance the potential of these mAb-based techniques.
Since the Philadelphia chromosome was discovered in 1960, studies over the past six decades have identified fusion genes, oncogenes that provide great diagnostic and therapeutic advantages because of their tumour-specific expression. This Timeline article revisits the spectrum of gene fusions in cancer and how the methods to identify them have evolved, and also discusses the implications of current, sequencing-based approaches for detection.
